BETHESDA, Md., June 8, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has made changes and substantially expanded its management team, adding several highly experienced executives. Ms. Linda Powers, who has served as Chairman of the Board since May 2007, has been appointed Chief Executive Officer. Dr. Anthony Maida, a well known senior executive in the field of cancer immune therapies, is joining NWBT as Chief Operating Officer on June 20th. Dr. Alton Boynton, who was the scientific founder of NWBT and has served as CEO since May 2007, is returning to his position as Chief Scientific Officer. Mr. Les Goldman, a former longtime partner at Skadden, Arps specializing in advanced technology commercialization, has been appointed Senior Vice President, Business Development. Dr. Marnix Bosch is continuing in his role as Chief Technology Officer.
As the newest member of the management team, Dr. Maida brings more than 20 years' experience in building oncology companies, with expertise in the business and financial aspects, the clinical and regulatory aspects, and the underlying science. Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings for these oncology companies. Among these experiences, he served for a period as CEO of CancerVax, an early leader in cancer vaccines. In that role, he raised the company's first $30 million of funding, and was responsible for conducting multi-hundred patient, multi-center clinical trials with the company's cancer vaccines. Prior to joining NWBT as COO, Dr. Maida was serving as global head of Oncology for a leading contract research organization that manages clinical trials in the U
|SOURCE Northwest Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved